The effects of tibolone

Gynecological Endocrinology

Volumn 12, Issue 3, 1998, Pages 213-220

  Rymer, J M ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Compliance; Non bleeding HRT; Tibolone

Indexed keywords

GONADORELIN AGONIST; TIBOLONE;

DRUG EFFECT; ENDOMETRIOSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW;

EID: 0031863965     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599809015548     Document Type: Review

References (46)

1. Stampfer MJ, Colditz CA. Estrogen replacement therapy and coronary heart disease. A qualitative assessment of the epidemiologic evidence. Prevent Med 1991;20:47-63
2. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991;90: 107-10
3. Birge SJ, Mortel KF. Estogens and the treatment of Alzheimer's disease. Am J Med 1997;103(3A): 365-455
4. Potter JD. Hormones and colon cancer. J Natl Cancer Inst 1995;87:1039-40
5. Ryan P, Harrison R, Blake GM, et al. Compliance with HRT after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99:355-8
6. Van der Vies J. Pharmacological studies with OD14. Maturitas 1987;(Suppl 1):15-24
7. Herschberger LG, Shipley EG, Meryer RH. Myotrophic activity of 19-nortestosterone and other steroids determined by the modified levator muscle method. Proc Soc Exp Biol Med 1953;83:175-80
8. Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogenic antagonistic and progestagenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990;35:535-41
9. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994;4:314-17
10. Lindsay R, McKay-Hart D, Kraszawski A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. Br Med J 1980;1209-1209
11. Kicovic PM, Cortes-Prieto J, Luisi M, et al. Placebo controlled cross-over study of the effects of Org OD14 in postmenopausal women. Reproduction 1982;6:81-91
12. Tax L, Goorissen EM, Kicovic PM. Clinical profile of Org OD14. Maturitas 1987;(Suppl 1):3-13
13. Volpe A, Facchinett F, Grasso A. Benefits and risks of different hormonal replacement therapies in postmenopausal women. Maturitas 1986;8:327-34
14. Milner MH, Sinnott MM, Cooke TM, et al. A two year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996;87:593-9
15. Rymer J, Chapman MG, Fogelman I, et al. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994;18:127-33
16. Sherwin B, Gelfand M, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47: 339-51
17. Nathorest-Boos J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15-20
18. Nathorst-Boos, Wiklund I, Mattson LA et al. Is sexual life influenced by transdermal oestrogen therapy - a double-blind controlled study in postmenopausal women. Acta Obstet Gynecol Scand 1992;72:656-60
19. Genazzani AR, Benedeck-Jaszman LJ, Hart DM, et al. Org OD14 and the endometrium. Maturitas 1991;13:243-51
20. Visser J, deCoert A, Feenstrah, et al. Endocrinological studies with Org OD14. Arzneimittelforsch/ Drug Res 1984;34:1010-17
21. Meuwissen JH, Wiegerinck MA, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995;21:121-5
22. De Aloysio D, Fabiani AG, Mauloni M, et al. Use of Org OD14 for the treatment of climacteric complaints. Maturitas 1987;(Suppl 1):49-65
23. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6
24. Walker ID, Davidson JF, Richards A, et al. The effects of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in menopausal women. Thromb Haemostat 1985;53:303-5
25. Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993; 128:259-62
26. Farish E, Barnes JF, Rolton HA, et al. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1994;20:215-19
27. Haenggi W, Lippuner K, Riesen W, et al. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997;104:708-17
28. Feher MD, Cox A, Levy A, et al. Short-term blood pressure and metabolic effects of tibolone in postmenopausal women with MIDDM. Br J Obstet Gynaecol 1996;103:281-3
29. Austin M. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14
30. Hardiman P, Nihoyannopoulous P, Kicovic P, et al. Cardiovascular effects of Org OD14 - a new steroidal therapy for climacteric symptoms. Maturitas 1991;13:235-42
31. Haenggi W, Linder HR, Birkhauser MH, et al. Microscopic findings of the nail-fold capillaries -dependence on menopausal status and HRT. Maturitas 1995;22:37-46
32. Crona N, Silvfverstolpe G, Samsoine G. A double blind cross-over study on the effects of ORG 0014 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol (Copenh) 1983; 102:451-5
33. Cagnaci A, Mallus E, Tuveri F, et al. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997; 82:251-3
34. Geusens P, Dequeker J, Gielen J, et al. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991;13:155-62
35. Studd J, Arnala I, Zambhere P, et al. Tibolone increases bone mass in women with previous fractures in a placebo controlled bicentre study. Osteoporosis Int 1996;6(Suppl 1):230
36. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late menopausal women. J Clin Endocrinol Metab 1997; 81:2419-22
37. Chetrite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17:135-40
38. Gompel A, Kandouz M, Siromachkova A, et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997;11(Suppl 1):77-9
39. Kloosterboer HJ. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal models of tumours. Gynecol Endocrinol 1997; 11(Suppl 1):63-8
40. Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994;101:53-6
41. Andrews WC. Continuous combined estrogen/ progestogen hormone replacement therapy. Clin Therap 1995;17:815-26
42. Von Dadelszen P, Gillmer MD, Gray MD, et al. Endometrial hyperplasia and adenocarcinoma during tibolone therapy. Br J Obstet Gynaecol 1994; 101:158-61
43. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059
44. Taskin O, Uryan I, Yalcinoglu AI, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 1997;67:40-5
45. Lindsay PC, Shaw RW, Coelingh Bennink HJ, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the GnRHa triptorelin. Fertil Steril 1996;65:342-8
46. Compston JE, Yamaguchi K, Croucher PI, et al. The effects of GnRHa on iliac crest cancellous bone structure in women with endometriosis. Bone 1995;16:261-267